You are here

Nanomaterial Safety Assessment Platform

Award Information
Agency: Department of Defense
Branch: Air Force
Contract: FA8650-11-M-6191
Agency Tracking Number: F103-031-0414
Amount: $99,970.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: AF103-031
Solicitation Number: 2010.3
Timeline
Solicitation Year: 2010
Award Year: 2011
Award Start Date (Proposal Award Date): 2011-04-18
Award End Date (Contract End Date): N/A
Small Business Information
410 Jan Davis Drive
Huntsville, AL -
United States
DUNS: 625694500
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Conrad Housand
 Products Division
 (256) 922-0802
 chousand@aegistg.com
Business Contact
 Georgina Chapman
Title: Business Development Analyst
Phone: (256) 922-0802
Email: gchapman@aegistg.com
Research Institution
 Stub
Abstract

ABSTRACT: Nanomaterials promise to bring critical advancements to technologies and products affecting multiple DoD mission areas. A major obstacle to realizing the strategic benefits of nanomaterials is the absence of computational risk assessment tools that allow nanomaterial developers to integrate and translate dose-response data and hazard rankings across in vitro and in vivo systems, between species and dose-routes, to assure the safety of nanomaterials in the work place and in their application. The overarching goal of this SBIR is to overcome these key barriers by developing the Nanomaterial Safety Assessment Platform (NSAP), an integrated quantitative pharmacokinetic and dose-response platform for determining the human exposure levels equivalent to those showing no toxicity in in vitro or in vivo assays, enabling rapid assessment of potential hazards posed by selected nanomaterials. The utility of the software will be demonstrated by predicting hazard rankings and human no effect levels for gold and silica nanomaterials using existing experimental data. In Phase II, capabilities for sensitivity analysis/variability analysis, conducting quantitative property-toxicity relationship analysis and derivation of dose-response models for transcriptional regulatory pathways will be developed, added, and extended to other nanomaterials. BENEFIT: AEgis Technologies expects this SBIR program to produce the first computational framework for rapidly deriving human safe exposure levels to nanomaterials through a novel integration of dose-response models, in vitro and in vivo data, and exiting in vivo/in vitro pharmacokinetic models. By enabling more rapid, more accurate nanomaterial safety assessments, the software will permit safer, more cost effective development and deployment of nanomaterial based materials supporting DoD missions.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government